IBI3020 / Innovent Biologics - LARVOL DELTA

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors (clinicaltrials.gov) - P1 | N=285 | Recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

New P1 trial • Solid Tumor

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies (PRNewswire) - "Innovent Biologics...announced completion of the first patient dosing for IBI3020, its first-in-class dual-payload CEACAM5 ADC, in Phase 1 clinical trial for the treatment of patients with advanced solid tumors....The study is an open-label, multi-regional Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IBI3020 in participants with advanced solid tumors, as well as determining the recommended Phase 2 dose (RP2D). The study has received IND approval in the U.S. recently and will be conducted in both China and the U.S."

Trial status • Solid Tumor

Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=285 | Not yet recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

New P1 trial • Solid Tumor